Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

The Food and Drug Administration has rehired the vaccine chief who resigned just two weeks ago. Dr. Vinay Prasad led the ...

At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for ...

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

Dr. Vinay Prasad’s rehiring was an unusual instance of a federal official targeted by the right-wing activist Laura Loomer ...

Dr. Vinay Prasad, a controversial critic of the US Food and Drug Administration who took a top role at the regulatory agency ...

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services ...

Vinay Prasad, the FDA’s top vaccine and gene therapy regulator, was the target of a right-wing pressure campaign over his ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

The Food and Drug Administration is launching a new program to ramp up the United States’ domestic pharmaceutical supply chain, the agency announced Thursday. The program, called FDA ...